ArticleOrphanet journal of rare diseases2020

Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study.

Eeva-Kaisa Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.